Zydus gets FDA nod for generic Gleevec, tentative OK for generic Jardiance
Patients with certain types of cancer have a new generic treatment option.
The Food and Drug Administration has cleared Zydus Cadila’s imatinib mesylate tablets, in dosage strengths of 100 mg and 400 mg.
The product is the generic of Novartis’ Gleevec tablets.
This medication is used to treat certain types of leukemia (blood cancer), bone marrow disorders, skin cancer and tumors of the stomach and digestive system.
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, in Ahmedabad.
A generic treatment option will soon be available for adults with Type 2 diabetes. The FDA has tentatively approved Zydus Cadila's empagliflozin tablets, in dosages strengths of 10 mg and 25 mg.
The product is the generic of Boehringer Ingelheim’s and Lilly’s Jardiance tablets.
The medication is used together with diet and exercise to improve blood sugar control in adults with Type 2 diabetes mellitus. It is also used to reduce the risk of cardiovascular death in adult patients with Type 2 diabetes mellitus and established cardiovascular disease.
The drug will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.